Disclosed herein is a novel use of a triterpenoid mixture for the treatment of multiple sclerosis (MS). The triterpenoid mixture consists of, ganoderic acid A (GAA), ganoderic acid B (GAB), ganoderic acid C (GAC), ganoderic acid C5(GAC5), ganoderic acid C6(GAC6), ganoderic acid D (GAD), ganoderic acid E (GAE), ganoderic acid G (GAG), and ganoderenic acid D. The triterpenoid mixture may be administered to a subject suffering from MS in a dose of about 1 to 10 mg/Kg to ameliorate or alleviate symptoms associated with MS.本案揭露一種將三萜混合物用於治療多發性硬化(multiple sclerosis, MS)之新穎用途。該三萜混合物係由靈芝酸A (ganoderic acid A, GAA)、靈芝酸B (ganoderic acid B, GAB)、 靈芝酸C (ganoderic acid C, GAC)、靈芝酸C5(ganoderic acid C5,GAC5)、靈芝酸C6(ganoderic acid C6, GAC6)、靈芝酸D (ganoderic acid D, GAD), 靈芝酸E (ganoderic acid E, GAE)、靈芝酸G (ganoderic acid G, GAG)、以及靈芝烯酸D (ganoderenic acid D) 所組成。可將該三萜混合物以大約 1 至 10 mg/kg 之劑量,施用於受多發性硬化(MS)所苦之個體,以減輕或緩和多發性硬化相關之症狀。